CStone Pharmaceuticals Company Description

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally.

The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, and systematic mastocytosis.

Its product pipeline includes Nofazinlimab (CS 1003), a PD-1 antibody to treat patients with hepatocellular carcinoma.

The company’s products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for the treatment of solid tumors; CS5001 to treat solid tumors and hematologic malignancies; and CS2013 and CS2015 for the treatment of autoimmune diseases.

CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.

CStone Pharmaceuticals

Country	Cayman Islands
Founded	2015
Industry	Biological Products, Except Diagnostic Substances
Employees	135
CEO	Jianxin Yang

Contact Details

Address: C1 Building Suzhou, 215123 China
Phone	86 512 8718 6550
Website	cstonepharma.com

Stock Details

Ticker Symbol	PH4
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
SIC Code	2836

Key Executives

Name	Position
Jianxin Yang	Chief Executive Officer
Weicong Ni	Chief Financial Officer
Ying Hua Zhang	Chief Operating Officer